Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update

Vivos Inc. secures FDA IDE approval, but financial impact remains unproven and long-dated.

What the company is saying

Vivos Inc. highlights FDA approval of its Feasibility IDE application on July 22, 2026, positioning this as a gateway to its first-in-human feasibility study at Mayo Clinic for non-resectable papillary thyroid carcinoma. The announcement repeatedly emphasizes regulatory progress, including the reduction of the safety follow-up period from five years to 24 months and anticipated DCGI approval in India by the end of 2026. The company frames its animal therapy business as validated, citing 17 certified U.S. clinics and over 200 animals treated, and details manufacturing expansion in both the United States and India. Language is consistently optimistic, projecting international expansion, moderate cash flow, and future commercialization, though these are not supported by realised financials. The tone is promotional, with forward-looking statements outnumbering realised milestones. No revenue, profit, or cash flow figures are disclosed, and the announcement omits any discussion of current financial health or operational risks.

What the data suggests

The only realised milestone is FDA IDE approval dated July 22, 2026, which allows but does not guarantee the start of a five-patient feasibility study. The reduction of the safety follow-up period to 24 months may accelerate data collection, but no patient enrollment or trial initiation is confirmed. The animal therapy business claims 17 certified clinics and over 200 animals treated, but provides no revenue or profitability data. Manufacturing expansion is described, including a contract with an Indian supplier and clean room upgrades, but without cost, capacity, or output figures. All financial projections are qualitative, with 'moderate cash flow' anticipated but unquantified. There is no evidence of commercial sales, binding contracts, or realised international expansion. The data set is incomplete, omitting all standard financial disclosures and providing no basis for assessing financial trajectory or operational efficiency.

Analysis

The announcement is framed with a highly positive tone, emphasizing regulatory milestones and future opportunities, but the majority of key claims are forward-looking and aspirational rather than realised. While the FDA IDE approval is a concrete milestone, most other claims—such as anticipated DCGI approval, international expansion, and projected cash flow—are not yet realised and lack supporting numerical evidence. The company discloses capital-intensive activities (manufacturing expansion, equipment procurement, clean room addition) but does not provide any immediate earnings impact or profitability metrics. The benefits from these investments are projected to materialize only after further regulatory approvals and clinical trial progress, which are expected by the end of 2026 or later. The absence of revenue, profit, or cash flow data means investors cannot assess whether operational progress is translating into financial value. The narrative inflates the signal by repeatedly referencing anticipated approvals, international expansion, and moderate cash flow without substantiating these with realised results.

Risk flags

• ●The absence of any revenue, profit/loss, or cash flow data prevents assessment of financial health or sustainability. This matters because operational progress does not necessarily translate into financial value, and investors have no visibility into burn rate or funding needs.
• ●Most key claims are forward-looking, including anticipated DCGI approval, international expansion, and projected cash flow, none of which are supported by binding agreements or realised results. This reliance on aspirational statements increases the risk that timelines slip or milestones are not achieved.
• ●The company is undertaking capital-intensive manufacturing expansion, including equipment procurement and clean room upgrades, but provides no detail on costs, funding sources, or payback period. This raises the risk of cost overruns or underutilised capacity if regulatory or commercial milestones are delayed.

Bottom line

Vivos Inc.'s FDA IDE approval is a real regulatory milestone, but the announcement is dominated by forward-looking claims, with most operational and financial benefits projected for late 2026 or beyond. The lack of any revenue, profit, or cash flow figures leaves investors unable to gauge whether these milestones will translate into financial returns. Manufacturing expansion and animal therapy growth are described in operational terms but lack evidence of commercial traction. The company's narrative is optimistic and promotional, but the absence of hard financial data or binding commercial agreements undermines its credibility. For investors, this update signals long-term potential but no near-term financial impact. The most important takeaway is that the investment case remains speculative until the company demonstrates realised revenue or clinical progress beyond regulatory approvals.

Announcement summary

(OTCQB: RDGL) Vivos Inc. received approval from the U.S. Food and Drug Administration (FDA) for its Feasibility Investigational Device Exemption (IDE) application on July 22, 2026, enabling the initiation of a first-in-human feasibility study at Mayo Clinic in Jacksonville, Florida, targeting patients with non-resectable papillary thyroid carcinoma. The study will initially enroll five patients to evaluate safety and feasibility, with the safety follow-up period reduced from five years to 24 months following FDA feedback. In India, Vivos Inc. has sufficient patient data from clinical work to prepare and submit an article for publication and anticipates receiving Drugs Controller General of India (DCGI) approval for its Principal Investigator at Healthcare Global Enterprises Hospital (HGC) to resume human treatments under the FDA-aligned protocol by the end of 2026. The animal therapy business supports 17 certified clinics across the U.S. that have treated more than 200 small animals and horses, and recently signed agreements with two veterinary clinics in California and one in North Carolina. Manufacturing validation activities are underway at the Applied Process Engineering Laboratory (APEL) in Richland, WA, with IsoPet shipments for veterinary use targeted by the end of this quarter, and a contract executed with a supplier in India to replicate production capabilities. Vivos Scientific India LLP positions the company for efficient supply to India and neighboring markets, and the company is offering its polymer and sterile hydrogel for research sale, having received interest from universities and major pharmaceutical companies. The company projects that these efforts will generate moderate cash flow while remaining focused on advancing treatments for cancerous tumors.

Disagree with this article?